Compare Albertsons Companies Inc (ACI) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Albertsons Companies Inc vs Enveric Biosciences Inc — how do they compare? Albertsons Companies Inc trades at $12.26 (market cap $5.89B), while Enveric Biosciences Inc trades at $1.45 (market cap $6.20M). The key difference: Albertsons Companies Inc is far larger — about 950× Enveric Biosciences Inc's market cap, and Albertsons Companies Inc pays a 5.61% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ACI | ENVB | |
|---|---|---|
Market Cap | $5.89B | $6.20M |
Sector | Consumer Staples | Health |
52-Week High | $19.74 | $17.40 |
52-Week Low | $11.03 | $1.27 |
Enterprise Value | $21.29B | $1.30M |
Dividend Yield | 5.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Albertsons (ACI) trades at $12.01, down 0.58% with bearish technical signals despite recent insider buying by the CEO and CFO. The company reported mixed Q2 2026 earnings with a miss on EPS expectations but maintains strong revenue growth trends. Valuation metrics show a high P/E ratio of 75.06 but attractive P/S of 0.08, while profitability remains challenged with net margins at just 0.08%.
The outlook remains cautious with analyst consensus at Buy (35%) but significant legal investigations and margin pressure creating headwinds. The $13.20 price target offers 10% upside potential, though execution risks and competitive grocery market dynamics require careful monitoring for sustained recovery.
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Albertsons Companies Inc
Albertsons is the second-largest traditional grocer in America, operating 2,276 stores under 24 banners in 34 states (as of the end of fiscal 2021). Around 75% of stores have pharmacies, while nearly 20% also sell fuel. Albertsons has a significant private-label operation, accounting for around 20% of sales (excluding fuel). While its own brand assortment is mainly manufactured by third parties, Albertsons operates 20 food production plants (as of the end of fiscal 2021). Albertsons is a top-two grocer in two thirds of its major markets (as of early 2022, according to company data), and virtually all of its sales come from the United States.
Read more on ACI →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
